200 related articles for article (PubMed ID: 19756559)
1. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.
Jiang D; Bai X; Zhang Q; Lu W; Wang Y; Li L; Müller M
Eur J Clin Pharmacol; 2009 Dec; 65(12):1187-93. PubMed ID: 19756559
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
3. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
Xu S; Liu L; Chen Y; Liu M; Lu T; Wang H; Liu S; Zhao M; Zhao L
Eur J Clin Pharmacol; 2018 May; 74(5):583-591. PubMed ID: 29340733
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.
Xu S; Chen Y; Zhao M; Guo Y; Wang Z; Zhao L
Eur J Pharm Sci; 2018 Sep; 122():170-178. PubMed ID: 29981400
[TBL] [Abstract][Full Text] [Related]
6. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
Guo Y; Hu C; He X; Qiu F; Zhao L
Drug Metab Pharmacokinet; 2012; 27(5):536-42. PubMed ID: 23099353
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of valproate in Chinese children with epilepsy.
Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
[TBL] [Abstract][Full Text] [Related]
8. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
9. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
10. Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.
Chen B; Xu Y; Jiang T; Feng R; Sun J; Zhang W; Yang W; Li J; Adeniyi O; Chen H
J Clin Pharm Ther; 2013 Dec; 38(6):504-11. PubMed ID: 23981149
[TBL] [Abstract][Full Text] [Related]
11. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Lane S; Al-Zubiedi S; Hatch E; Matthews I; Jorgensen AL; Deloukas P; Daly AK; Park BK; Aarons L; Ogungbenro K; Kamali F; Hughes D; Pirmohamed M
Br J Clin Pharmacol; 2012 Jan; 73(1):66-76. PubMed ID: 21692828
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
Mei S; Feng W; Zhu L; Li X; Yu Y; Yang W; Gao B; Wu X; Fang F; Zhao Z
Eur J Clin Pharmacol; 2018 Aug; 74(8):1029-1036. PubMed ID: 29666902
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of
Shen X; Chen X; Lu J; Chen Q; Li W; Zhu J; He Y; Guo H; Xu C; Fan X
Front Pharmacol; 2022; 13():1037239. PubMed ID: 36506519
[No Abstract] [Full Text] [Related]
14. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
15. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Yoo HD; Kim MS; Cho HY; Lee YB
Eur J Clin Pharmacol; 2011 Sep; 67(9):889-98. PubMed ID: 21476064
[TBL] [Abstract][Full Text] [Related]
17. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
18. Effects of
Zheng XX; You YX; Zhao LL; Du Y; Xu SQ; Tang DQ
Pharmacogenomics; 2023 Feb; 24(3):153-162. PubMed ID: 36718958
[No Abstract] [Full Text] [Related]
19. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
20. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
